Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atazanavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.94 |
| ▸ | MLNR | O43193 | 1/20 | 0.94 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.94 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.94 |
| ▸ | CCKAR | P32238 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | GHSR | Q92847 | 1/20 | 0.94 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.94 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.94 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | CTSD | P07339 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | PGC | P20142 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atazanavir SCHEMBL29362158 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL27785902 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL341700 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL28121836 | 1.00 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL825777 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL7993264 | 0.97 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2716 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459989-B2 | Antibody therapies for human immunodeficiency virus (HIV) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2025-10-16 | — | — | US | claimed |
| CN-120053378-A | Ginsenoside Rh2 composition and preparation method and application thereof | 澳门大学 | 2025-05-30 | — | — | CN | claimed |
| US-12257264-B2 | Combination therapy for HIV with adenosine derivative and capsid inhibitors | BRII BIOSCIENCES, INC. (US) | 2025-03-25 | — | — | US | claimed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| US-12156901-B2 | Treatment of immunosuppressed subjects | NANTCELL, INC. (US) | 2024-12-03 | — | — | US | claimed |
| CN-118662643-A | Application of hormone medicine composition in preparation of medicine for treating osteoarthritis | 中南大学湘雅医院 | 2024-09-20 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024124212-A1 | DEVICES AND METHODS FOR DETECTION OF DISEASE BIOMARKERS AND THERAPEUTIC EFFECTIVENESS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4281081-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Brii Biosciences, Inc. (US) | 2023-11-29 | — | — | EP | claimed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| EP-1583542-B1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES INC (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2008022242-A2 | SYNTHESIS OF PROPYL PHENOXY ETHERS AND USE AS DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2007124383-A2 | 1,1'-BINAPHTHYL-BASED INHIBITORS OF NAD+-DEPENDENT DEACETYLASE ACTIVITY AND SIR2-FAMILY MEMBERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070161611-A1 | POLYCYCLIC PHENOLIC COMPOUNDS AND USE IN TREATING VIRAL INFECTIONS | MIGENIX CORPORATION | 2007-07-12 | — | — | US | claimed |
| CN-1980666-A | Process and novel forms for the preparation of atazanavir bisulfate | BRISTOL MYERS SQUIBB CO (US) | 2007-06-13 | — | — | CN | claimed |
| WO-2007062528-A1 | POLYCYCLIC PHENOLIC COMPOUNDS AND USE IN TREATING VIRAL INFECTIONS | MIGENIX CORPORATION (US) | 2007-06-07 | — | — | WO | claimed |
| EP-1755596-A2 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | Bristol-Myers Squibb Company (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005108349-A2 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050256202-A1 | Process for preparing atazanavir bisulfate and novel forms | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-17 | — | — | US | claimed |